侵袭性成人T细胞白血病/淋巴瘤异基因造血干细胞移植的前瞻性多中心研究
该前瞻性多中心研究纳入80例侵袭性成人T细胞白血病/淋巴瘤(ATL)患者,74例接受一线化疗,其中39例后续接受异基因造血干细胞移植(allo-SCT)。自一线治疗起2年总生存(OS)率为45%,时间依赖性分析显示allo-SCT显著改善生存(风险比0.32)。移植后3年OS和无进展生存率均为52%,1年非复发死亡率和累积复发率分别为15%和35%。
要点
- 侵袭性ATL患者接受allo-SCT可显著改善生存,时间依赖性分析风险比为0.32。
- 移植时未达完全缓解或部分缓解是预后不良的主要危险因素。
- 移植后3年OS和无进展生存率均为52%,1年非复发死亡率为15%。
核心结论
- 研究结果支持符合条件的侵袭性ATL患者接受异基因造血干细胞移植的获益。
研究设计与样本
- 前瞻性多中心研究,2016年至2024年纳入80例ATL患者,74例接受一线化疗,39例后续接受allo-SCT。
主要发现
- 自一线治疗起2年OS率为45%,时间依赖性分析显示allo-SCT显著改善生存(风险比0.32)。
- 移植后3年OS和无进展生存率均为52%,1年非复发死亡率为15%,累积复发率为35%。
- 移植时未达完全缓解或部分缓解是预后不良的主要危险因素。
- 对可评估的缓解期患者进行HTLV-1/ATL分子和流式细胞术监测,发现移植后肿瘤克隆不可检测。
关键数值与推荐
- 移植时27例达完全缓解,5例达部分缓解,7例为疾病稳定或进展。
- 供者来源包括单倍体(56%)、同胞全合(26%)和无关供者(18%)。
- 预处理方案为塞替派-白消安-氟达拉滨。
临床怎么用
- 对于符合条件的侵袭性ATL患者,可考虑在一线化疗后序贯异基因造血干细胞移植。
- 移植前应尽可能达到完全缓解或部分缓解以改善预后。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adult T-cell leukemia/lymphoma (ATL) is associated with a dismal prognosis in aggressive subtypes, with a median overall survival (OS) of less than one year. In Japan, first line chemotherapy followed by allogeneic stem cell transplantation (allo-SCT) is recommended for eligible patients, yet this strategy is scarcely reported elsewhere, especially among ethnic minorities. We prospectively evaluated the feasibility and outcome of allo-SCT in this setting. Between 2016 and 2024, 80 ATL patients were enrolled; 74 (median age 50 years) received frontline chemotherapy (CHO(E)P regimen +/-Brentuximab Vedotin in CD30 positive cases). Of these, 39 subsequently proceeded to allo-SCT using a Thiotepa-Busulfan-Fludarabine conditioning regimen after at least one line of chemotherapy. Two-year OS from first line therapy was 45 %. Time-dependent analysis demonstrated a significant survival benefit for allo-SCT (hazard ratio, 0.32). Uncontrolled disease was the primary reason for transplant ineligibility. At transplantation, 27 patients were in complete remission (CR,) 5 in partial response (PR) and 7 had stable/progressive disease. Donor sources included haploidentical (56%), matched sibling (26%), and unrelated donors (18%). Three-year OS and progression-free survival were both 52%, while one-year non-relapse mortality and cumulative relapse incidence were 15% and 35%, respectively. Absence of CR/PR at allo-SCT was the main risk factor for poor outcomes. Tailored HTLV-1/ATL molecular and flow-cytometric monitoring of assessable patients in remission, revealed that tumor clones became undetectable after allo-SCT, suggesting a potent graft-versus-ATL effect. Overall, our findings support the benefit of allo-SCT in eligible ATL patients. Clinical Trial Identifier: NCT05237245.
引用
- Marçais A, Lhermitte L, Avettand Fenoel V, et al. Allogeneic stem cell transplantation in aggressive Adult T cell leukemia/lymphoma: a prospective multicenter study. Blood Adv. 2026. PMID: 42843318. doi:10.1182/bloodadvances.2026020323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。